Amiloride bioequivalence studies
Executive Summary
FDA guidelines state that studies should consist of a two treatment single dose crossover design comparing the test product with the reference product, MS&D's Midamor, in 24 males. "Analytical data for 24 subjects should be evaluated by ANOVA to determine if there are statistically significant differences (p. < 0.05) between the dosing groups," the guidelines state. "Evaluation of bioequivalence should be based upon comparison of the plasma AUC, Cmax, and Tmax values between the two drug products".
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.